Psagot Value Holdings’s NRX Pharmaceuticals NRXP Stock Holding History

Psagot Value Holdings’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$10K	–	381
2021 Q4	$10K	Buy	+200	New	+$14.4K	﹤0.01%	321

Other funds holding NRXP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Psagot Value Holdings's NRXP Position: Q1 2022 in Review

Psagot Value Holdings sold out of NRX Pharmaceuticals (NRXP) in Q1 2022, closing a stake of 200 shares — an estimated $10K sold.

Psagot Value Holdings first reported a position in NRXP in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 34 funds tracked by Wall St. Rank hold NRXP as of Q1 2022.

Psagot Value Holdings reported no remaining NRX Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Psagot Value Holdings sold 200 NRX Pharmaceuticals shares in Q1 2022, an estimated $10K.
Psagot Value Holdings first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Psagot Value Holdings's NRX Pharmaceuticals position peaked at $10K in Q4 2021.
34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2022.

Based on Psagot Value Holdings's 13F filing for Q1 2022, filed 16 May 2022.